Trial to Assess the Safety of Vorapaxar in Japanese Subjects With Cerebral Infarction (P05005; MK-5348-017)

NCT00684515 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

90

Enrollment

INDUSTRY

Sponsor class

Conditions

Cerebral Infarction

Interventions

DRUG: Vorapaxar 2.5 mg
DRUG: Vorapaxar 1 mg
DRUG: Placebo
DRUG: Aspirin 75-150 mg

Sponsor

Merck Sharp & Dohme LLC